<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7019553\results\search\disease\results.xml">
  <result pre="In Hungary, between February 2017 and July 2019, 70 confirmed" exact="measles" post="cases were reported, raising questions about the adequacy of"/>
  <result pre="requirement, we developed a quick ‘three-in-one’ or ‘triple’ MMR (measles," exact="mumps" post="and rubella) indirect ELISA (IgG); an assay format that"/>
  <result pre="we combined our current results with previously published data (Ntotal" exact="measles" post="= 3523). Evaluation of anti-mumps and anti-rubella humoral antibody"/>
  <result pre="an effective and low-cost approach for the prevention of measles," exact="mumps" post="and rubella infections. Key words IgG immunity indirect ELISA"/>
  <result pre="and low-cost approach for the prevention of measles, mumps and" exact="rubella" post="infections. Key words IgG immunity indirect ELISA measles MMR"/>
  <result pre="mumps and rubella infections. Key words IgG immunity indirect ELISA" exact="measles" post="MMR mumps rubella vaccine fig-count: table-count: ref-count: page-count: Introduction"/>
  <result pre="rubella infections. Key words IgG immunity indirect ELISA measles MMR" exact="mumps" post="rubella vaccine fig-count: table-count: ref-count: page-count: Introduction Despite the"/>
  <result pre="infections. Key words IgG immunity indirect ELISA measles MMR mumps" exact="rubella" post="vaccine fig-count: table-count: ref-count: page-count: Introduction Despite the existence"/>
  <result pre="fig-count: table-count: ref-count: page-count: Introduction Despite the existence of effective" exact="measles" post="(M) and measles-containing vaccines (MCV), resurgence of measles cases"/>
  <result pre="of effective measles (M) and measles-containing vaccines (MCV), resurgence of" exact="measles" post="cases in the USA and across Europe has occurred,"/>
  <result pre="since the 1960s. The introduction of the trivalent measles, mumps," exact="rubella" post="(MMR) vaccines started in the 1970s [2] (in Hungary"/>
  <result pre="form of modern and safe tri- and tetravalent (measles, mumps," exact="rubella" post="and varicella; MMRV) vaccines. However, the risk of continued"/>
  <result pre="MMRV) vaccines. However, the risk of continued widespread circulation of" exact="measles" post="in EU/EEA still exists, since significant immunity gaps persist,"/>
  <result pre="historical and current vaccination coverage [3]. Despite regional outbreaks of" exact="measles" post="infections, in 2016, globally fewer than 1 00 000"/>
  <result pre="(MCV2) [4]. In spite of the improving vaccine coverage tendencies," exact="measles" post="incidence increased again to 89.5 per 1 million population"/>
  <result pre="WHO reports, the largest outbreaks occur in countries with low" exact="measles" post="vaccination coverage. However, outbreaks occurred even in countries with"/>
  <result pre="high national vaccination rates [6]. Lately, an alarming surge of" exact="measles" post="cases was experienced in countries neighbouring Hungary. From 2017"/>
  <result pre="From 2017 to 2018, Ukraine had the largest increase in" exact="measles" post="cases worldwide [7, 8]. In 2018, Ukraine reported &amp;gt;54"/>
  <result pre="cases worldwide [7, 8]. In 2018, Ukraine reported &amp;gt;54 000" exact="measles" post="cases; more than the entire EU. The total estimated"/>
  <result pre="more than the entire EU. The total estimated number of" exact="measles" post="cases for the first 5 months of 2019 was"/>
  <result pre="4% received only one of the two-shot vaccination series. Regarding" exact="parotitis" post="epidemica (mumps), the last accessible ECDC surveillance report is"/>
  <result pre="the UK were responsible for 77% of these cases. The" exact="mumps" post="childhood vaccination coverage in Hungary is ≥99% (MCV1 and"/>
  <result pre="infection is predominantly by virus importation [11]. In Hungary, the" exact="rubella" post="vaccine was introduced in 1990 in the form of"/>
  <result pre="2007 and 2018, WHO reports only 10 cases [12]. Measles," exact="mumps" post="and rubella statistics (cases per year) based on WHO"/>
  <result pre="2018, WHO reports only 10 cases [12]. Measles, mumps and" exact="rubella" post="statistics (cases per year) based on WHO measles and"/>
  <result pre="mumps and rubella statistics (cases per year) based on WHO" exact="measles" post="and rubella ‘elimination country profile for Hungary’ data (i.e."/>
  <result pre="rubella statistics (cases per year) based on WHO measles and" exact="rubella" post="‘elimination country profile for Hungary’ data (i.e. the number"/>
  <result pre="doses of MCV in 2017 [13]. Despite the estimated 99%" exact="measles" post="vaccination coverage in Hungary [12, 14] (Supplementary Fig. S1),"/>
  <result pre="(Supplementary Fig. S1), from February 2017 to July 2019, 70" exact="measles" post="cases were laboratory confirmed according to the European Centre"/>
  <result pre="(excluding neonates), and were categorised based on changes introduced in" exact="measles" post="and MMR immunization schedules. Grey, shaded rectangles indicate measles"/>
  <result pre="in measles and MMR immunization schedules. Grey, shaded rectangles indicate" exact="measles" post="outbreaks, black squares show the recommended age of the"/>
  <result pre="of recent outbreaks worldwide, not only of measles, but also" exact="mumps" post="and rubella (MMR) infections [15–19], and because of waning"/>
  <result pre="outbreaks worldwide, not only of measles, but also mumps and" exact="rubella" post="(MMR) infections [15–19], and because of waning of immunity"/>
  <result pre="serum bank consisting of anonymous patient sera was established (Ntotal" exact="measles" post="=3523 measles, Nmumps = 1736 mumps and Nrubella ="/>
  <result pre="sera was established (Ntotal measles =3523 measles, Nmumps = 1736" exact="mumps" post="and Nrubella = 1736) from routine laboratory samples at"/>
  <result pre="laboratory examination requests from all over Hungary. In case of" exact="measles" post="serosurvey, in order to give a more accurate estimate"/>
  <result pre="of current measurements (previously we tested 1985 serum samples for" exact="measles" post="[24], of which the data of 1787 samples have"/>
  <result pre="together with the current data; ‘cumulative’ data for measles, Ntotal" exact="measles" post="= 3523). Serum samples were from all age groups"/>
  <result pre="age groups (beginning from the era before the implementation of" exact="measles" post="vaccine, through several different vaccine types, manufacturers and vaccination"/>
  <result pre="present), and were categorised based on past changes introduced in" exact="measles" post="and MMR immunisation schedules (Table 1). The age group"/>
  <result pre="has been based on the landmarks in the history of" exact="measles" post="and MMR vaccination schedules in Hungary, as detailed in"/>
  <result pre="‘Patients vaccinated between 1991–1995’, since this individual received the first" exact="measles" post="(MMR) vaccine in May 1991 Patients born before 1969"/>
  <result pre="born before 1969 Unvaccinated patients, wild-type infections. 1969: introduction of" exact="measles" post="vaccine in Hungary (live, attenuated Leningrad-16 strain produced in"/>
  <result pre="and 1977 From 1969 to 1974, a single dose of" exact="measles" post="vaccine was administered in mass campaigns to persons 9–27"/>
  <result pre="were re-vaccinated at the age of 11 years with monovalent" exact="measles" post="vaccine in a scheduled manner. Consequently, the first individuals"/>
  <result pre="are the first individuals who benefited from the reminder monovalent" exact="measles" post="vaccine at the age of 11. In 1999 the"/>
  <result pre="1988 Patients vaccinated between 1988 and 1990 In 1989 the" exact="rubella" post="vaccine was introduced, and the monovalent measles reminder vaccine"/>
  <result pre="In 1989 the rubella vaccine was introduced, and the monovalent" exact="measles" post="reminder vaccine at age 11 was started1990: Introduction of"/>
  <result pre="strain (live, attenuated)1999: Measles–mumps–rubella re-vaccination (reminder shot) instead of monovalent" exact="measles" post="vaccine1999: Introduction of GSK PLUSERIX – Measles Schwarz Strain"/>
  <result pre="important milestones of the Hungarian vaccination history (e.g. the first" exact="measles" post="vaccine was introduced in Hungary in 1969; in 1990,"/>
  <result pre="used purified, inactivated native virus preparations, derived from disrupted cells;" exact="measles" post="Edmonston strain cultured in Vero cells (PIP013 Bio-Rad), mumps"/>
  <result pre="cells; measles Edmonston strain cultured in Vero cells (PIP013 Bio-Rad)," exact="mumps" post="Enders strain cultured in BSC-1 cells (PIP014 Bio-Rad), rubella"/>
  <result pre="Bio-Rad), mumps Enders strain cultured in BSC-1 cells (PIP014 Bio-Rad)," exact="rubella" post="HPV-77 strain cultured in Vero cells (PIP044 Bio-Rad). Antigen"/>
  <result pre="each third was incubated overnight at 4–6 °C with measles," exact="mumps" post="and rubella antigens (100 µl/well), respectively (Fig. 2, Table"/>
  <result pre="was incubated overnight at 4–6 °C with measles, mumps and" exact="rubella" post="antigens (100 µl/well), respectively (Fig. 2, Table 2). Testing"/>
  <result pre="with a series of doubling, four-point dilutions of recombinant antigens;" exact="measles" post="virus Priorix, Schwarz strain nucleocapsid protein (Abcam ab74559, source:"/>
  <result pre="strain nucleocapsid protein (Abcam ab74559, source: Saccharomyces cerevisiae) 1.66–0.207 µg/ml," exact="mumps" post="virus wild-type, Gloucester strain, nucleocapsid protein (Abcam ab74560, source:"/>
  <result pre="nucleocapsid protein (Abcam ab74560, source: S. cerevisiae) 0.832–0.104 µg/ml, recombinant" exact="rubella" post="virus capsid protein (Abcam ab43034, source: Escherichia coli) 2–0.25"/>
  <result pre="assays, results of negative and low positive sample pools, international" exact="measles" post="and rubella standards (3rd WHO International Standard for Anti-Measles,"/>
  <result pre="of negative and low positive sample pools, international measles and" exact="rubella" post="standards (3rd WHO International Standard for Anti-Measles, NIBSC code"/>
  <result pre="1st WHO International Standard Human, NIBSC code RUBI-1-94), and the" exact="mumps" post="quality control reagent (Anti-Mumps Quality Control Reagent Sample1) obtained"/>
  <result pre="testing, optimisation and comparisons, the following validated kits were used:" exact="measles" post="IgG: Novalisa, Immunolab, Euroimmun, Sekisui-Virotech, Serion, Siemens Enzygnost; mumps"/>
  <result pre="used: measles IgG: Novalisa, Immunolab, Euroimmun, Sekisui-Virotech, Serion, Siemens Enzygnost;" exact="mumps" post="IgG: Novalisa, Immunolab, Euroimmun, Sekisui-Virotech, Vircell; rubella IgG: Novatec,"/>
  <result pre="Serion, Siemens Enzygnost; mumps IgG: Novalisa, Immunolab, Euroimmun, Sekisui-Virotech, Vircell;" exact="rubella" post="IgG: Novatec, Immunolab, Euroimmun, DiaPro, Vircell. Because our samples"/>
  <result pre="negative samples were measured using indirect immunofluorescence assays, using measles," exact="mumps" post="and rubella virus-infected cells, IIF (IgG) (Euroimmun). In case"/>
  <result pre="were measured using indirect immunofluorescence assays, using measles, mumps and" exact="rubella" post="virus-infected cells, IIF (IgG) (Euroimmun). In case of commercial"/>
  <result pre="tests, the following recombinant viral nucleocapsid antigen coatings were selected:" exact="measles" post="0.83 µg/ml, mumps 0.416 µg/ml and rubella 1.0 µg/ml"/>
  <result pre="recombinant viral nucleocapsid antigen coatings were selected: measles 0.83 µg/ml," exact="mumps" post="0.416 µg/ml and rubella 1.0 µg/ml (R2 standards ≥0.97,"/>
  <result pre="coatings were selected: measles 0.83 µg/ml, mumps 0.416 µg/ml and" exact="rubella" post="1.0 µg/ml (R2 standards ≥0.97, R2 samples ≥0.93) (Supplementary"/>
  <result pre="based concentrations: 0.83 µg/mL, 0.416 µg/mL, 1.0 µg/mL for measles," exact="mumps" post="and rubella, respectively. Optimal inactivated pathogen-based coating concentrations: 2.8"/>
  <result pre="coating concentrations: 2.8 µg/mL, 3.0 µg/mL, 0.4 µg/mL for measles," exact="mumps" post="and rubella, respectively. Sample number (n): N=28 (Samples were"/>
  <result pre="following sensitivity–specificity pairs were selected 0.985–0.975, 0.935–0.911, 0.989–0.946 for measles," exact="mumps" post="and rubella, respectively. According to the ‘experimental approach’, cut-off"/>
  <result pre="15 samples, ODnegative sample ⩽ 0.28, 0.37, 0.34 for measles," exact="mumps" post="and rubella, respectively; data not shown). Cut-off values calculated"/>
  <result pre="the statistically computed values. Typical dose–response curves obtained for measles," exact="mumps" post="and rubella standards are shown in Figure 5. Analytical"/>
  <result pre="computed values. Typical dose–response curves obtained for measles, mumps and" exact="rubella" post="standards are shown in Figure 5. Analytical values, such"/>
  <result pre="3. We selected randomly chosen negative samples from the measles," exact="mumps" post="and rubella groups (30 each) that were verified using"/>
  <result pre="selected randomly chosen negative samples from the measles, mumps and" exact="rubella" post="groups (30 each) that were verified using indirect immunofluorescent"/>
  <result pre="microscopy. We found 93%, 90% and 96% correspondence for measles," exact="mumps" post="and rubella, respectively (data not shown). Fig. 4. Cohen's"/>
  <result pre="10^ ((LOGx0-x)*p)). Adjusted R2 values: 0.97, 0.97, 0.99 for measles," exact="mumps" post="and rubella, respectively. Measurement ranges: 0.025–12.5 mIU/mL, 0.02–10.0 arbitrary"/>
  <result pre="mIU/mL, 0.02–10.0 arbitrary U/mL, 2.0 – 265 mU/mL for measles," exact="mumps" post="and rubella, respectively. Cut-off values: 0.15 mIU/mL, 0.15 arbitrary"/>
  <result pre="+ 3SD) extinction (OD) values: 0.08, 0.10, 0.08 for measles," exact="mumps" post="and rubella, respectively. LOQ (mean + 10SD) extinction (OD)"/>
  <result pre="+ 10SD) extinction (OD) values: 0.20, 0.23, 0.20 for measles," exact="mumps" post="and rubella, respectively. Assay characteristics: cost, ease and time"/>
  <result pre="clusters of the population. Regarding anti-measles antibodies, cumulative data (Ntotal" exact="measles" post="= 3523 serum samples) show that the lowest seropositivity"/>
  <result pre="= 0.00004 and P = 0.0015, respectively) (Fig. 10). For" exact="mumps" post="(N = 1736 serum samples), the least protected groups"/>
  <result pre="different from the adjacent age groups. In the case of" exact="rubella" post="(N = 1736 serum samples), the least protected groups"/>
  <result pre="of results. Considering the age-independent totality of samples, the anti-measles," exact="mumps" post="and rubella IgG antibody titres were inadequate in 10.16%,"/>
  <result pre="Considering the age-independent totality of samples, the anti-measles, mumps and" exact="rubella" post="IgG antibody titres were inadequate in 10.16%, 8.18% and"/>
  <result pre="section, in Hungary, between February 2017 and July 2019, 70" exact="measles" post="cases were laboratory confirmed according to ECDC reports [5]."/>
  <result pre="[5]. During the epidemics of 2017, there have been 36" exact="measles" post="cases in Hungary (five imported, 26 import-related, four unknown/not"/>
  <result pre="may have underlaid the infections [12]. The last case of" exact="parotitis" post="epidemica reported in Hungary was a non-vaccinated 35-year-old man,"/>
  <result pre="summer of 2018. Between 2012 and 2016, Hungary reported 21" exact="mumps" post="cases [12, 26]. In the 2007 local mumps outbreak,"/>
  <result pre="reported 21 mumps cases [12, 26]. In the 2007 local" exact="mumps" post="outbreak, the epidemic started from an individual who returned"/>
  <result pre="close communities of unvaccinated people (student houses, schools) [11]. Considering" exact="rubella" post="in Hungary, between 2007 and 2018, WHO reported only"/>
  <result pre="the end of 1990s and beginning of 2000s, when ~100" exact="rubella" post="cases per year were reported (WHO statistics). By 2006,"/>
  <result pre="decreased by 80% (22 reported cases in year 2006). Measles," exact="mumps" post="and rubella statistics (cases per year) are shown in"/>
  <result pre="80% (22 reported cases in year 2006). Measles, mumps and" exact="rubella" post="statistics (cases per year) are shown in Supplementary Figure"/>
  <result pre="year) are shown in Supplementary Figure S2. In 1969, the" exact="measles" post="vaccine was introduced in Hungary in the form of"/>
  <result pre="reconstituted vaccine was not fully characterised [5]. These relatively high" exact="measles" post="seronegativity ratios may have been a consequence of vaccine"/>
  <result pre="who were vaccinated in the early era with a singular" exact="measles" post="vaccine. Following the 1988–1989 epidemics, persons born between 1973"/>
  <result pre="** in Figure 9 later were re-vaccinated or contracted wild-type" exact="measles" post="infection (and thus mounted high IgG antibody response), in"/>
  <result pre="[35]. The R0 estimates are highest for measles, intermediate for" exact="mumps" post="and generally lowest for rubella [35]. For measles, R0"/>
  <result pre="highest for measles, intermediate for mumps and generally lowest for" exact="rubella" post="[35]. For measles, R0 is often cited as 12–18,"/>
  <result pre="for ~95% herd immunity. This means that each person with" exact="measles" post="can infect 12–18 other individuals in a completely susceptible"/>
  <result pre="efficient seroconversion on population level) is the official target for" exact="measles" post="elimination. In the literature, R0 and HIT values are"/>
  <result pre="considered normative [44], entire antigen repertoire-based ELISA/EIA methods of measles," exact="mumps" post="and rubella IgG antibody detection are considered rather than"/>
  <result pre="[44], entire antigen repertoire-based ELISA/EIA methods of measles, mumps and" exact="rubella" post="IgG antibody detection are considered rather than a good"/>
  <result pre="of the marker. Although the half-lives of antibodies against measles," exact="mumps" post="and rubella are relatively long, unexpected responses cannot be"/>
  <result pre="marker. Although the half-lives of antibodies against measles, mumps and" exact="rubella" post="are relatively long, unexpected responses cannot be excluded, whereby"/>
  <result pre="the ‘three-in-one’ assay is highlighted by recent outbreaks of measles," exact="mumps" post="and rubella infections in several countries. This triple assay"/>
  <result pre="assay is highlighted by recent outbreaks of measles, mumps and" exact="rubella" post="infections in several countries. This triple assay is based"/>
  <result pre="of potential gaps in anti-measles immunity of the population. For" exact="mumps" post="and rubella, our preliminary data suggest satisfactory immunity levels."/>
  <result pre="References References 1.HaralambievaIHet al. (2015) Variability in humoral immunity to" exact="measles" post="vaccine: new developments. Trends in Molecular Medicine21, 789–801.26602762 2.TabacchiGet"/>
  <result pre="parents’ decision on the vaccination of their children against measles," exact="mumps" post="and rubella: a systematic review and meta-analysis. Vaccines &amp;amp;"/>
  <result pre="Disease Control (2019) Insufficient vaccination coverage in EU/EEA fuels continued" exact="measles" post="circulation. Available at https://ecdc.europa.eu/en/news-events/ecdc-insufficient-vaccination-coverage-eueea-fuels-continued-measles-circulation Accessed 24 July 2019. 4.ZimmermanLAet"/>
  <result pre="https://ecdc.europa.eu/en/news-events/ecdc-insufficient-vaccination-coverage-eueea-fuels-continued-measles-circulation Accessed 24 July 2019. 4.ZimmermanLAet al. (2019) Progress toward" exact="measles" post="elimination – European region, 2009–2018. MMWR. Morbidity and Mortality"/>
  <result pre="665–668. Available at https://www.cdc.gov/mmwr/preview/mmwrhtml/00001472.htm 6.collab: World Health Organization (2019) New" exact="measles" post="surveillance data from WHO. World Health Organization. Published online:"/>
  <result pre="US Travelers. Pediatrics144, e20190414. doi: 10.1542/peds.2019-0414.31209161 11.MolnárZet al. (2007) Local" exact="mumps" post="outbreak in Hungary, 2007. Weekly Releases (1997–2007) European Centre"/>
  <result pre="and Control12, 3167. 12.collab: World Health Organization (2017) Measles and" exact="rubella" post="elimination country profile Hungary. Available at http://www.euro.who.int/__data/assets/pdf_file/0013/401116/HUN.pdf?ua=1 13.collab: European"/>
  <result pre="at http://www.euro.who.int/__data/assets/pdf_file/0013/401116/HUN.pdf?ua=1 13.collab: European Centre for Disease Control (2019). Monthly" exact="measles" post="and rubella monitoring report, April 2019. 14.collab: World Health"/>
  <result pre="13.collab: European Centre for Disease Control (2019). Monthly measles and" exact="rubella" post="monitoring report, April 2019. 14.collab: World Health Organization (2018)."/>
  <result pre="The Lancet390, 2490–2502. 17.LewnardJA and GradYH (2018) Vaccine waning and" exact="mumps" post="re-emergence in the United States. Science Translational Medicine10, eaao5945.29563321"/>
  <result pre="20.LiuYet al. (2018) Waning immunity of one-dose measles-mumps-rubella vaccine to" exact="mumps" post="in children from kindergarten to early school age: a"/>
  <result pre="445–452.29478347 21.BankampBet al. (2019) Successes and challenges for preventing measles," exact="mumps" post="and rubella by vaccination. Current Opinion in Virology34, 110–116.30852425"/>
  <result pre="al. (2019) Successes and challenges for preventing measles, mumps and" exact="rubella" post="by vaccination. Current Opinion in Virology34, 110–116.30852425 22.KontioMet al."/>
  <result pre="of Infectious Diseases206, 1542–1548.22966129 23.GibneyKBet al. (2019) Emergence of attenuated" exact="measles" post="illness among IgG positive/IgM negative measles cases, Victoria, Australia"/>
  <result pre="(2019) Emergence of attenuated measles illness among IgG positive/IgM negative" exact="measles" post="cases, Victoria, Australia 2008–2017. Clinical Infectious Diseases. Published online:"/>
  <result pre="of Infectious Diseases189, S116–S122.15106100 28.OrensteinWAet al. (1986) Appropriate age for" exact="measles" post="vaccination in the United States. Developments in Biological Standardization65,"/>
  <result pre="consequences. Epidemiology and Infection147, e7. 33.AgócsMMet al. (1992) The 1988–1989" exact="measles" post="epidemic in Hungary: assessment of vaccine failure. International Journal"/>
  <result pre="Diseases52, 911–916.21427399 35.EdmundsWJet al. (2000) The pre-vaccination epidemiology of measles," exact="mumps" post="and rubella in Europe: implications for modelling studies. Epidemiology"/>
  <result pre="35.EdmundsWJet al. (2000) The pre-vaccination epidemiology of measles, mumps and" exact="rubella" post="in Europe: implications for modelling studies. Epidemiology and Infection125,"/>
  <result pre="Interpreting serological surveys using mixture models: the seroepidemiology of measles," exact="mumps" post="and rubella in England and wales at the beginning"/>
  <result pre="surveys using mixture models: the seroepidemiology of measles, mumps and" exact="rubella" post="in England and wales at the beginning of the"/>
  <result pre="of Clinical Pathology106, 170–174.8712168 41.WardBJet al. (1995) Cellular immunity in" exact="measles" post="vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite"/>
  <result pre="al. (1995) Cellular immunity in measles vaccine failure: demonstration of" exact="measles" post="antigen-specific lymphoproliferative responses despite limited serum antibody production after"/>
  <result pre="45.Dorigo-ZetsmaJWet al. (2015) Immune status of health care workers to" exact="measles" post="virus: evaluation of protective titers in four measles IgG"/>
  <result pre="workers to measles virus: evaluation of protective titers in four" exact="measles" post="IgG EIAs. Journal of Clinical Virology69, 214–218.26209410 46.TischerAet al."/>
  <result pre="(2007) Vaccinated students with negative enzyme immunoassay results show positive" exact="measles" post="virus-specific antibody levels by immunofluorescence and plaque neutralisation tests."/>
 </snippets>
</snippetsTree>
